Abstract: The present disclosure relates to a breathing assistance apparatus for providing a breathing assistance to a user. The breathing assistance apparatus includes a first/second source configured with a first/second buffer. The first/second fluid is controllably transferred from the first/second source to the first/second buffer using any or combination of a first/second pressure regulators and one or more first/second valves. A mixing chamber configured with the first buffer and the second buffer to receive and mix the first fluid and the second fluid. A delivery tank configured with the mixing tank to controllably receive the third fluid through one or more fourth valves and a third pressure regulator. A user feed mask having an inlet configured with the delivery tank and user's face facilitating breathing assistance to the user.

Abstract: The present disclosure relates to a breathing assistance apparatus for providing a breathing assistance to a user. The breathing assistance apparatus includes a first/second source configured with a first/second buffer. The first/second fluid is controllably transferred from the first/second source to the first/second buffer using any or combination of a first/second pressure regulators and one or more first/second valves. A mixing chamber configured with the first buffer and the second buffer to receive and mix the first fluid and the second fluid. A delivery tank configured with the mixing tank to controllably receive the third fluid through one or more fourth valves and a third pressure regulator. A user feed mask having an inlet configured with the delivery tank and user's face facilitating breathing assistance to the user.

Abstract: A 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diasterisomer is described which is a better inhibitor of topoisomerase I than either the diastereoisomeric mixture 5(RS)-(2?-hydroxyethoxy)-20(S)-camptothecin, or the 5(R)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer. Pharmaceutical compositions of the 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer are also described as are methods of using the compound for the inhibition of topoisomerase I and for the treatment of cancer.

Abstract: A 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diasterisomer is described which is a better inhibitor of topoisomerase I than either the diastereoisomeric mixture 5(RS)-(2?-hydroxyethoxy)-20(S)-camptothecin, or the 5(R)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer. Pharmaceutical compositions of the 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer are also described as are methods of using the compound for the inhibition of topoisomerase I and for the treatment of cancer.

Abstract: A 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diasterisomer is described which is a better inhibitor of topoisomerase I than either the diastereoisomeric mixture 5(RS)-(2?-hydroxyethoxy)-20(S)-camptothecin, or the 5(R)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer. Pharmaceutical compositions of the 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer are also described as are methods of using the compound for the inhibition of topoisomerase I and for the treatment of cancer.

Abstract: A crystalline form of 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer of 5(RS)-(2?-hydroxyethoxy)-20(S)-camptothecin is described that is characterized by having an X-ray powder diffraction pattern comprising one or more peak intensities expressed in degrees 2? that are selected from the group consisting of 7.2±0.1, 9.4±0.1, 11.02±0.1, 12.00±0.1, 14.54±0.1, 15.2±0.1, 18.92±0.1, 21.86±0.1, 22.74±0.1 and 26.42±0.1. Methods of making and using the compound are also described.

Abstract: A 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diasterisomer is described which is a better inhibitor of topoisomerase I than either the diastereoisomeric mixture 5(RS)-(2?-hydroxyethoxy)-20(S)-camptothecin, or the 5(R)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer. Pharmaceutical compositions of the 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer are also described as are methods of using the compound for the inhibition of topoisomerase I and for the treatment of cancer.

Abstract: A crystalline form of 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer of 5(RS)-(2?-hydroxyethoxy)-20(S)-camptothecin is described that is characterized by having an X-ray powder diffraction pattern comprising one or more peak intensities expressed in degrees 2? that are selected from the group consisting of 7.2±0.1, 9.4±0.1, 11.02±0.1, 12.00±0.1, 14.54±0.1, 15.2±0.1, 18.92±0.1, 21.86±0.1, 22.74±0.1 and 26.42±0.1. Methods of making and using the compound are also described.

Abstract: Described are pharmaceutically acceptable salts of a compound of formula (I) its tautomeric forms, its stereoisomers or its polymorphs, which is obtained by treating the compound of formula (I) with an acid selected from the group consisting of hydrohalo acid selected from the group consisting of hydrochloric acid or hydrobromic acid, acetic acid; sulfuric acid, nitric acid, phosphoric acid, boric acid, perchloric acid, tartaric acid, maleic acid, citric acid, methanesulfonic acid, benzoic acid, ascorbic acid, salicylic acid and benzene sulfonic acid wherein R1 represents substituted (C1–C6) alkyl wherein the substituent(s) is selected from mono (C1–C6) alkylamino or di (C1–C6) alkylamino; R2 represents hydroxy; R3, R4 and R5 represent hydrogen; and R6 represents hydrogen, or substituted (C1–C6) alkyl, wherein the substituent(s) is selected from halogen, hydroxy or (C1–C6) alkoxy and methods for using these compounds.

Abstract: The present invention relates to pharmaceutically acceptable salts formed by the compounds of general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs and pharmaceutically acceptable compositions containing them. The present invention also relates to a process for the preparation of the above said pharmaceutically acceptable salts, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, and pharmaceutical compositions containing them.

Abstract: Novel water soluble C-ring analogues of 20(S)-camptothecin having the general formula 1. All the compounds of the formula 1 are prepared from the compounds of the general formula 2 having 20(S)-chiral carbon. The compounds of the formula 1 possess potent anti-cancer and anti-viral properties. The invention also provides an alternate process for the preparation of known C-5 substituted compounds of the formula 1.

Abstract: Novel water soluble C-ring analogues of 20(S)-camptothecin having the general formula 1, All the compounds of the formula 1 are prepared from the compounds of the general formula 2 having 20(S)-chiral carbon where R1 to R5 have the meaning given above. The compounds of the formula 1 possess potent anti-cancer and anti-viral properties.

Abstract: Novel water soluble C-ring analogs of 20(S)-camptothecin having the formula 1. ##STR1## The compounds of the formula 1 are prepared from the compounds of the formula 12 having C-20(S) chiral carbon. The compounds of the formula 1 possess potent anti-cancer and anti-viral properties.

Abstract: Novel taxane derivatives and intermediates having the formula 1. ##STR1## and a process for the preparation of the compounds of the formula 1 from 14-.beta.-hydroxy-10-deacetylbaccatin III of formula 2 ##STR2## and pharmaceutically acceptable compositions containing the taxane derivatives and intermediates of formula 1.